The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP
Open accessAbstract
Glutamate regulates the function of central nervous system (CNS), in part, through the cAMP and/or IP3/DAG second messenger‐associated metabotropic glutamate receptors (mGluRs). The mGluR5 antagonist 2‐methyl‐6‐(phenylethynyl)‐pyridine (MPEP) has been extensively used to elucidate potential physiological and pathophysiological functions of mGluR5. Unfortunately, recent evidence indicates significant non‐specific actions of MPEP, including inhibition of NMDA receptors. In contrast, in vivo and in vitro characterization of the newer mGluR5 antagonist 3‐[(2‐methyl‐1,3‐thiazol‐4‐yl)ethynyl]pyridine (MTEP) indicates that it is more highly selective for mGluR5 over mGluR1, has no effect on other mGluR subtypes, and has fewer off‐target effects than MPEP. This article reviews literature on both of these mGluR5 antagonists, which suggests their possible utility in neurodegeneration, addiction, anxiety and pain management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“It is well established that the excitatory neurotransmitter glutamate acts through two classes of receptors — fast ligand-gated ionotropic receptors and slower G-protein coupled receptors (51,58).”
BackgroundThe Role of Excitatory Amino Acids and NMDA Receptors in Traumatic Brain Injury
Faden, A. I., Demediuk, P., Panter, S. S., & Vink, R. (1989) · Science · doi:10.1126/science.2567056 · Cited by 1,508 · cited 1×
“Because this prevalent amino acid helps maintain homeostasis in the adult brain, pathological alterations in its release, receptors or signaling cascade can mediate temporary and or permanent effects that disrupt normal function (48,62,72,102, 103,132,150,193,215).”
BackgroundSelf-citationAddiction: A Disease of Learning and Memory
Hyman, S. E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1414 · Cited by 980
Tu, J. C., Xiao, B., Yuan, J. P., Lanahan, A. A., Leoffert, K., Li, M., Linden, D. J., & Worley, P. F. (1998) · Neuron · doi:10.1016/s0896-6273(00)80589-9 · Cited by 862 · cited 2×
“These may reflect differences in desensitization factors (3,66,136); regulation of intracellular calcium signaling (93); interactions with iGluRs and ion channels via homer; PSD-95 complexes and Shank (30,92,168,199,200); signaling through various heterotrimeric Gprotein subunits (45,67); regulation of mGluR mediated…”
BackgroundInteraction with the NMDA receptor locks CaMKII in an active conformation
Bayer, K.-U., De Koninck, P., Leonard, A. S., Hell, J. W., & Schulman, H. (2001) · Nature · doi:10.1038/35081080 · Cited by 732
Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725 · cited 6×
“MPEP completely inhibits quisqualate-stimulated PI hydrolysis (IC50 = 36 nM) (69) and is without effect on human mGluR6 ( 10 ìM), mGluR1b ( 30 ìM), or mGlu2, -3, -4a, -7b, or -8a ( 100 ìM) (69).”
BackgroundInfluentialThe Shank family of scaffold proteins
Sheng, M., & Kim, E. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.11.1851 · Cited by 578
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Historical review: molecular and cellular mechanisms of opiate and cocaine addiction
Nestler, E. J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.02.005 · Cited by 425
Cited by
Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
Jeffrey Conn, P., Christopoulos, A., & Lindsley, C. W. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2760 · Cited by 1,063
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598
Silverman, J. L., Tolu, S. S., Barkan, C. L., & Crawley, J. N. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.201 · Cited by 438
Metadata
- Authors
- Lea, P. M., & Faden, A. I.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2006-06
- Volume
- 12
- Issue
- 2
- Pages
- 149-166
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2024628377
- Cited by
- 170
- References
- 10
- FWCI
- 4.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP. https://app.cochat.ai/papers/10.1111/j.1527-3458.2006.00149.x
- The paper
- Lea, P. M., & Faden, A. I. (2006). Metabotropic Glutamate Receptor Subtype 5 Antagonists MPEP and MTEP. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2006.00149.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.